Publications by authors named "Craig M Comisar"
Article Synopsis
- Zavegepant (ZAVZPRET™) is a selective medication for treating acute migraines in adults, targeting specific receptors related to migraine pathways.
- A comprehensive analysis of its pharmacokinetics determined how zavegepant is absorbed, distributed, and eliminated from the body, utilizing data from multiple clinical trials.
- The findings revealed that zavegepant has low bioavailability rates when taken intranasally (5.1%) or orally (0.65%), with factors like age and sex not significantly affecting its pharmacokinetics, but certain conditions (like moderate liver impairment) could impact its clearance.